Document is current
Any future updates will be listed below
-
Authors
Kuru, Erkin https://orcid.org/0000-0002-2356-0858
Rittichier, Jonathan
de Puig, Helena https://orcid.org/0000-0002-5368-6996
Flores, Allison https://orcid.org/0000-0002-2655-8323
Rout, Subhrajit
Han, Isaac
Reese, Abigail E.
Bartlett, Thomas M.
De Moliner, Fabio
Bernier, Sylvie G.
Galpin, Jason D. https://orcid.org/0000-0003-1923-5312
Marchand, Jorge https://orcid.org/0000-0002-7765-610X
Bedell, William
Robinson-McCarthy, Lindsey
Ahern, Christopher A.
Bernhardt, Thomas G.
Rudner, David Z.
Collins, James J. https://orcid.org/0000-0002-5560-8246
Vendrell, Marc https://orcid.org/0000-0002-5392-9740
Church, George M. https://orcid.org/0000-0001-6232-9969
-
Funding
Funding for this research was provided by:
U.S. Department of Energy (Grant DE-FG02-02ER63445)
- License Information
-
More Information
Article History
Received: 14 March 2024
Accepted: 24 July 2024
First Online: 5 September 2024
Competing interests
: E.K., H.P., J.J.C., and G.M.C. are cofounders of ExtRNA. J.R. and G.M.C. are cofounders of enplusone. G.M.C. is a cofounder of 64-x, EnEvolv, and GRO Biosciences. For a complete list of G.M.C.’s financial interests, please visit arep.med.harvard.edu/gmc/tech.html. J.J.C. is a cofounder and director at Sherlock Biosciences. The authors declare no competing interests.
